| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.27 | 4e-08 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.24 | 1e-06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.091 | 0.05 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.084 | 0.07 |